Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver fibrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    382 result(s) found for: Liver fibrosis. Displaying page 3 of 20.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000685-39 Sponsor Protocol Number: NN9931-4296 Start Date*: 2016-10-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomised, double-blind, ...
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) GR (Completed) BG (Completed) FI (Completed) SE (Completed) NL (Completed) AT (Completed) BE (Completed) FR (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002073-56 Sponsor Protocol Number: Aramchol-018 Start Date*: 2020-01-06
    Sponsor Name:Galmed Research and Development, Ltd.
    Full Title: A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMO...
    Medical condition: Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004405-34 Sponsor Protocol Number: GS-US-231-0101 Start Date*: 2010-09-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmon...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000204-14 Sponsor Protocol Number: GS-US-428-4194 Start Date*: 2019-09-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended) FR (Completed) ES (Restarted) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005628-13 Sponsor Protocol Number: IRRB/34/12 Start Date*: 2012-12-19
    Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE
    Full Title: Transplantation of Human Fetal Liver Cells for the Treatment of Patients with Decompensated Liver Cirrhosis
    Medical condition: liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10019669 Hepatic fibrosis and cirrhosis HLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    14.1 10019805 - Hepatobiliary disorders 10019664 Hepatic failure and associated disorders HLT
    14.1 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003566-39 Sponsor Protocol Number: NN9500-4656 Start Date*: 2021-06-29
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000295-42 Sponsor Protocol Number: GFT505-212-7 Start Date*: 2012-09-11
    Sponsor Name:GENFIT
    Full Title: A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).
    Medical condition: Patients with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004058-32 Sponsor Protocol Number: 2014RESP02M(14-01-14) Start Date*: 2014-12-19
    Sponsor Name:Norfolk and Norwich University Hospital NHS Foundation Trust
    Full Title: The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004449-18 Sponsor Protocol Number: HEP201 Start Date*: 2019-04-10
    Sponsor Name:Promethera Biosciences
    Full Title: Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH).
    Medical condition: NASH is characterized by steatosis, inflammation and cytological ballooning with varying amounts of fibrosis. Patients with NASH are at risk of cardiovascular morbidity and mortality. In chronic li...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    20.0 10019805 - Hepatobiliary disorders 10019708 Hepatic steatosis PT
    20.0 10019805 - Hepatobiliary disorders 10041970 Steatosis hepatic LLT
    20.0 10019805 - Hepatobiliary disorders 10019669 Hepatic fibrosis and cirrhosis HLT
    20.0 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    20.1 10019805 - Hepatobiliary disorders 10064704 Decompensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-002538-14 Sponsor Protocol Number: 218672 Start Date*: 2023-06-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: 17-beta-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001267-39 Sponsor Protocol Number: VX15-770-123 Start Date*: 2016-06-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-019884-12 Sponsor Protocol Number: INFIRE-001 Start Date*: 2010-12-17
    Sponsor Name:Universitätsklinikum Aachen
    Full Title: Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection
    Medical condition: Patients with chronic hepatitis B infection and a relevant grade of fibrosis (histological >= F2)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005355-83 Sponsor Protocol Number: PTC124-GD-021e-CF Start Date*: 2015-10-01
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Phase 3 extension Study of Ataluren (PTC124®) in Patients with Nonsense Mutation Cystic Fibrosis
    Medical condition: Nonsense Mutation Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) NL (Prematurely Ended) FR (Prematurely Ended) BG (Prematurely Ended) GR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004581-34 Sponsor Protocol Number: PTC124-GD-021-CF Start Date*: 2014-09-15
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients with Nonsense Mutation Cystic Fibrosis
    Medical condition: Nonsense Mutation Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) DE (Temporarily Halted) NL (Completed) ES (Completed) GB (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001987-31 Sponsor Protocol Number: COMBAT_T2_NASH_002 Start Date*: 2020-08-05
    Sponsor Name:Deutsche Diabetes Forschungsgesellschaft e.V.
    Full Title: COMBined Active Treatment in Type 2 Diabetes with NASH
    Medical condition: Diabetes mellitus type 2 (T2D) and non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10051599 Diabetes mellitus management PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003172-32 Sponsor Protocol Number: MASH Start Date*: 2018-05-23
    Sponsor Name:Imperial College London
    Full Title: Maraviroc Add-On Therapy for Steatohepatitis in HIV – The MASH Study
    Medical condition: Non alcoholic steatohepatitis (NASH) in patients with HIV mono-infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005215-33 Sponsor Protocol Number: CLJN452A2202 Start Date*: 2016-06-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, 3- part, adaptive design, multicenter study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with non-alcoholic steatoh...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006227-38 Sponsor Protocol Number: 11.017 Start Date*: 2012-05-01
    Sponsor Name:Ove B. Schaffalitzky de Muckadell
    Full Title: “Assessment of fibrotic liver disease in a medical admission ward and intervention with losartan as antifibrotic therapy in patients with alcoholic liverdisease”
    Medical condition: Fibrotic alcoholic liver disease is in early stages often completely asymptomatic. Fully developed cirrhosis affect a wide range of physiological conditions. Eksamples are portal hypertension and f...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    14.1 10019805 - Hepatobiliary disorders 10001626 Alcoholic liver damage, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004374-18 Sponsor Protocol Number: GS-US-384-1943 Start Date*: 2017-08-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis.
    Medical condition: Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) BE (Completed) GB (Completed) DE (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004012-22 Sponsor Protocol Number: MGL-3196-11 Start Date*: 2019-07-25
    Sponsor Name:Madrigal Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce P...
    Medical condition: Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 11:52:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA